Takeda ended an eight-year partnership with Denali, returning full rights to Denali’s DNL593 ahead of the program’s Phase 1 steps. The termination arrives as Takeda continues restructuring, which the companies say has affected collaboration coverage across the pipeline. DNL593 is now back under Denali control, shifting development responsibilities and timing assumptions that had been built into the original collaboration. For Takeda, the move trims obligations during a period when larger pharma is prioritizing portfolio simplification. The break underscores how program-level economics can change when restructuring meets long-horizon biology partnerships. Denali’s near-term challenge will be re-establishing clinical and operational plans for DNL593 following the rights return.